ISRCTN76960238已完成不适用
A randomised, double-blind, placebo-controlled phase IV trial to assess the clinical benefit of Genacol®, a food supplement made of a proprietary collagen hydrolysate (1200 mg/day), over a period of 24 weeks, in subjects with joint pain at the lower, upper limbs or at the lumbar spine
utraveris (France)0 个研究点目标入组 200 人开始时间: 2010年2月22日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Men and women over 50 years with joint pain (hip, knee, elbow, shoulder, hand and lumbar spine) over 30 mm on a 0-100 mm visual analogue scale.
排除标准
- •1. Unlikely to cooperate in the study
- •2. Poor compliance anticipated by the investigator
- •3. Participating in another trial at the same time or within the previous 1 month with active therapeutic intervention (except if the patient only performed the screening visit without taking the tested supplement)
研究者
相似试验
进行中（未招募）
1 期
A study to investigate if use of FOL-005 can increase hair growth.EUCTR2017-003809-17-DEFollicum AB60
已完成
不适用
A double-blind, randomised, placebo-controlled phase III study of the efficacy of a bivalent Pseudomonas aeruginosa flagella vaccine in patients with cystic fibrosisNutritional, Metabolic, EndocrineCystic fibrosisISRCTN98785888The Society for the fight of Cystic Fibrosis (The Gesellschaft zur Bekämpfung der Mukoviszidose e.V.) (Germany)483
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled Phase IIIb Study investigating changes in immunological parameters and cutaneous reactivity induced by a short course immunotherapy with ALK grass tablets.EUCTR2006-005263-26-ESALK-Abelló, S.A.
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to asthmatic subjects after the onset of a respiratory viral infection for the prevention or attenuation of asthma symptoms caused by respiratory virusesEUCTR2009-017480-42-GBSynairgen Research Ltd147
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to COPD patients after the onset of a respiratory viral infection for the prevention or attenuation of COPD symptoms caused by respiratory viruses - Phase II: Inhaled SNG001 in COPD subjectsEUCTR2010-022110-29-GBSynairgen Research Limited166